Table 1 The engagement of aptamer-based nanoformulations in anti-cancer therapy
Type | Nanoformulation | Indication | Reference |
|---|---|---|---|
Anti-HER2 aptamer (HApt) | Gold nanoparticles | HER-2 positive breast cancer | [207] |
CD133 aptamer | Salinomycin-loaded PEGylated PLGA nanoparticles | Osteosarcoma | [208] |
CD133 aptamers A15 and EGFR aptamers CL4 | Salinomycin-loaded PLGA nanoparticles | Hepatocellular carcinoma | [209] |
EGFR-targeting aptamers | Triple-functional pRNA-3WJ nanoparticles | Triple-negative breast cancer | [210] |
EpCAM aptamer | Doxorubicin-loaded PEG-PLGA nanoparticles | Non-small cell lung cancer | [211] |
Mucin 1 aptamer | Gold nanoparticle-hybridized graphene oxide | Breast cancer | [212] |